FDC Limited (founded in 1936) is among India's leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations and among the world's foremost manufacturers and marketers of Oral Rehydration Salts (ORS). Headquartered in Mumbai, India, FDC Limited is a fully integrated research-oriented pharmaceutical company engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company is a prominent player in the Indian pharmaceutical industry, renowned for its expertise in developing specialized formulations.
FDC has a market capitalization of ₹8,220 crore. For FY25, the company reported revenue of ₹2,108 crore and profit of ₹267 crore. The company is almost debt-free, with a Debt to Equity ratio of 0.0 for FY24, strengthening its financial position significantly.
The latest quarterly results for Q3FY25 show operating revenue at ₹464 crore, a 1.3% YoY growth from ₹458 crore in Q3FY24. However, EBITDA for Q3FY25 stood at ₹47 crore, down 44.3% YoY. Profit After Tax (PAT) dropped 53.2% YoY to ₹37 crore.
For the full financial year FY24, FDC Limited reported an increase in operating revenue with an 8.9% growth for the full fiscal year. Profit after tax (PAT) for FY24 was reported at ₹305 crore, marking an increase of 57.4% year-over-year. Net profit margins grew from 10.9% in FY23 to 15.7% in FY24.
* FY25 Performance: Revenue: ₹2,108 Cr, Profit: ₹267 Cr
* Q3 FY25 Performance: Operating Revenue: ₹464 crore, Profit After Tax (PAT): ₹37 crore
* FY24 Performance: Operating Revenue Growth: 8.9%, Profit After Tax (PAT): ₹305 crore, Net Profit Margin: 15.7%
* Market Capitalization: ₹8,220 crore
* Promoter Holding: 69.7%
FDC Limited manufactures and markets pharmaceutical products in India and internationally. The company offers specialized formulations for various therapeutic segments, including anti-infective, gastrointestinal, ophthalmic, vitamins, minerals, dietary supplements, cardiac, anti-diabetes, respiratory, gynaecology, dermatology, and analgesics; as well as anti-oxidants, balanced energy and protein drinks, and vitamins and nutraceuticals, along with various active pharmaceutical ingredients.
Some of FDC's leading brands in India include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zathrin, Zipod, Cotaryl, and Mycoderm. The company provides its products under brand names such as Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Vitcofol, Ziglim, Ziglim Plus 2, Electral, and Enerzal.
Anti-infective medicines contribute 42% of revenues, followed by gastrointestinal (24%), vitamins/minerals (7%), ophthalmology (6%), cardiac (7%), dermatology (4%), and others (11%).
FDC Limited is an India-based company principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations, and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. FDC initiated the concept of Oral Rehydration Salts (ORS) and is now a pioneer in the segment with its brand Electral. The company's manufacturing facilities are strategically located with its registered office at B-8 MIDC Industrial Area, Waluj, Aurangabad, Maharashtra.
On June 30, 2022, FDC Ltd.'s shareholding pattern showed public holdings of 20.1%, domestic institutional investor holdings of 6.08%, foreign institutional investor holdings of 4.34%, and promoter holdings of 69.5%. Ms. Meera Ramdas Chandavarkar is a leading promoter with a 19.4% share.
The company delivered revenue growth of 9.1% in 9MFY25, driven by robust performance across all business segments, except for US Formulations. The export formulations business witnessed a 20.7% YoY decline in 9MFY25, primarily due to lower sales in the US market. On the other hand, the API business demonstrated strong momentum, recording a 25.6% YoY growth in Q3FY25 and 25.1% YoY growth in 9MFY25. Domestic formulations showed growth, particularly driven by flagship brands such as Electral, Zifi, Enerzal, and Zifi-O.
The company has delivered a sales growth of 9.46% over the past five years. However, the company continues to focus on expanding its product portfolio and international presence, with particular emphasis on making Electral a global brand across various territories. FDC Ltd operates in a highly competitive pharmaceutical industry but maintains its position through continuous innovation in specialized formulations and strong brand recognition, particularly in the ORS segment where it pioneered the concept in India.
